Literature DB >> 24984950

[Implementation of the S3 prostate cancer guideline in daily clinical practice: results of a survey among urologists].

M Fröhner1, C Khan, R Koch, S G Schorr, M Wirth.   

Abstract

BACKGROUND: Beside the quality of a guideline, the implementation in daily practice is of particular concern. The aim of this study was to determine the degree of implementation of the interdisciplinary S3 guideline on diagnostics and treatment of prostate cancer.
METHODS: A questionnaire containing questions regarding the implementation of the S3 guideline was sent to 119 private practice urologists and 37 urologists working in hospitals. Comparisons were made with the χ(2) test.
RESULTS: The response rate was 63%. Of the responding urologists, 93% reported that they used the guideline in the daily practice, while 95% considered the strong recommendations of the guideline as treatment standard. Urologists working in a hospital recommended the guideline less frequently to their patients as source of information (30 versus 58%, p = 0.0283), but more frequently to other physicians (95 versus 72%, p = 0.0294), than private practice urologists did.
CONCLUSION: The interdisciplinary S3 guideline on diagnostics and treatment of prostate cancer is used by the vast majority of urologists in their daily practice. The strong guideline recommendations are considered as treatment standard. A more compact presentation and a propagation of the guideline outside the urologic community might improve implementation of the guideline.

Entities:  

Mesh:

Year:  2014        PMID: 24984950     DOI: 10.1007/s00120-014-3518-0

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  4 in total

1.  [Assessment and implementation of guidelines].

Authors:  H Kirchner; M Fiene; G Ollenschläger
Journal:  Rehabilitation (Stuttg)       Date:  2003-04       Impact factor: 1.113

2.  [Which components should living guidelines contain?].

Authors:  L Weissbach
Journal:  Urologe A       Date:  2012-01       Impact factor: 0.639

3.  [What is most important is what comes across : Urological guidelines from the target group's point of view].

Authors:  J Busch; C Röllig; L Weissbach; C Kempkensteffen; S Hinz; C Jahnke; M Schostak; M Lein; S Weikert; C Stephan; S Deger; G Ollenschläger; K Miller; M Schrader
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

4.  How can we improve guideline use? A conceptual framework of implementability.

Authors:  Anna R Gagliardi; Melissa C Brouwers; Valerie A Palda; Louise Lemieux-Charles; Jeremy M Grimshaw
Journal:  Implement Sci       Date:  2011-03-22       Impact factor: 7.327

  4 in total
  6 in total

1.  [Guideline adherence - is more always better?].

Authors:  M J Nothacker
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

2.  [Residents training in private practice : Conflicts between circumstances, willingness, and reality].

Authors:  J Salem; H Borgmann; J Bründl; E-M Lausenmeyer; V Lent; A Schroeder; A Heidenreich
Journal:  Urologe A       Date:  2016-08       Impact factor: 0.639

3.  [Use of the S3 guidelines for early detection of prostate cancer in urological practices].

Authors:  D Tiedje; O Quer; B Breil; A J Schrader; C Bothe; K Kruse; M Bögemann; N Donner-Banzhoff; A Semjonow
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

4.  Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy.

Authors:  Jeannette Kratzenberg; Georg Salomon; Pierre Tennstedt; Paolo Dell'Oglio; Derya Tilki; Axel Haferkamp; Markus Graefen; Katharina Boehm
Journal:  World J Urol       Date:  2018-01-13       Impact factor: 4.226

5.  Assessing health-related quality of life in urology - a survey of 4500 German urologists.

Authors:  A Schmick; M Juergensen; V Rohde; A Katalinic; A Waldmann
Journal:  BMC Urol       Date:  2017-06-19       Impact factor: 2.264

6.  Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey.

Authors:  Sanny Kappen; Verena Jürgens; Michael H Freitag; Alexander Winter
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.